Nephros Inc

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nephros Inc reports first profitable quarter, eyes growth opportunities

Nephros Inc delivered a strong performance in Q3 2024, achieving profitability and operational efficiency gains.
While facing revenue challenges and liquidity concerns, the company's strategic initiatives and focus on financial discipline position it for growth.
Opportunities in new markets and customer engagement through digital tools provide avenues for future expansion.
Balancing growth pursuits with financial prudence will be crucial for Nephros Inc's sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH ORANGE, NJ, Oct. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced preliminary financial results for the quarter ended September 30, 2020.

Nephros Announces Preliminary Third Quarter Revenues of $2.1 Million

  Daron Evans to Remain Senior Science Advisor and CEO of Specialty Renal Products

Nephros Names Andy Astor President and Chief Executive Officer

Nephros, Inc. (NEPH) CEO Daron Evans on Q2 2020 Results - Earnings Call Transcript

SOUTH ORANGE, NJ, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Net Revenue down 32% due to COVID-19 Interruptions

Nephros Reports Second Quarter Financial Results

SOUTH ORANGE, NJ, July  29, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its second quarter 2020 financial results on Wednesday, August 5, 2020 and will host a conference call that same day at 4:30 PM ET, during which management will discuss the company's financial results and provide a general business overview. 

Nephros Announces Second Quarter 2020 Financial Results Conference Call

  Nephros SequaPath™, a new microbial screening system, used to evaluate 88 building water samples across four US geographic regions

Potable Water in Buildings Unoccupied During COVID-19 Pandemic Contains Far More Bacteria than in Occupied Buildings; Legionella does not Predominate

SOUTH ORANGE, N.J., July  13, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Nephros, Inc.  (Nasdaq:  NEPH ), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting virtually at the upcoming Zooming with LD event on Thursday, July 23rd at 11:00 AM ET. Daron Evans, President & CEO and Andy Astor, COO & CFO of Nephros will be giving the presentation and answering questions from investors.

Nephros to Present at Zooming with LD

Nephros Announces Preliminary Financial Results for Second Quarter 2020

SOUTH ORANGE, NJ, June  18, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc.(Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it is set to join the Russell Microcap® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a preliminary list of additions posted June 5.

Nephros Set to Join Russell Microcap® Index

SOUTH ORANGE, N.J., June  02, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Nephros, Inc.  (Nasdaq:  NEPH ), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting at the upcoming Virtual Summer Summit on Tuesday, June 9th at 10:55 AM ET. Andy Astor, COO & CFO of Nephros, will be giving the presentation and answering questions from investors.

Nephros to Present at the Virtual Summer Summit

Nephros, Inc. to Hold Virtual Annual Meeting of Stockholders

Nephros Reports First Quarter Financial Results

Nephros has been struggling lately, but the selling pressure may be coming to an end soon.

Nephros Sees Hammer Chart Pattern: Time to Buy?

Anticipates $2.6 Million Net Revenues, Approximately 45% Growth Over 2019

Nephros Announces Preliminary Financial Results for First Quarter 2020

Medical Device Veteran Hired to Drive FDA Clearance and Market Launch

Specialty Renal Products Announces Appointment of Tony Robinson as Vice President of Operations

SOUTH ORANGE, NJ, March  10, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc.(Nasdaq: NEPH), a commercial stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting at the Sidoti Spring 2020 Investor Conference on Thursday, March 26that 9:10 am EDT. Andy Astor, COO & CFO of Nephros, will be giving the presentation and answering questions from investors.

Nephros to Present at the Sidoti Spring 2020 Investor Conference

Nephros, Inc. (NEPH) CEO Daron Evans on Q4 2019 Results - Earnings Call Transcript

SOUTH ORANGE, NJ, Feb.  20, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will file its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020 and will host a conference call that same day at 4:30 PM ET, during which management will discuss the company's financial results and provide a general business overview.

Nephros Announces Fourth Quarter and Full Year 2019 Financial Results Conference Call

SOUTH ORANGE, NJ, Jan.  31, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a  commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a firm commitment underwritten offering of 937,500 shares of common stock at a price to the public of $8.00 per share for aggregate gross proceeds of approximately $7,500,000, before underwriting discounts and offering expenses. The offering is expected to close on or about February 4, 2020, subject to the satisfaction of customary closing conditions.

Nephros Announces Pricing of $7.5 Million Underwritten Offering of Common Stock

SOUTH ORANGE, NJ, Jan.  09, 2020  (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced that it has formally launched PluraPathTM, the only commercially available portable water pathogen detection system designed to provide actionable data for infection control teams on up to 15 different pathogens from a single water sample, in approximately one hour.  

Nephros Announces Launch of PluraPath™, a Real-Time, Portable, Water Pathogen Detection System

Anticipates $10.3 Million Full-Year Revenue, Approximately 82% Growth Over 2018;    Fourth Quarter Year-Over-Year Revenue Growth Approximately 99%

Nephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019

Cerus

Northern Oil and Gas

Syros Pharmaceuticals

Zynga

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Red-Hot Stocks Trading Under $10 With Incredible Upside Potential

News for Nephros Inc Stock (NEPH)